Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Search Close Search
Page Menu

Vector Innovation Discovery and Engineering (VIDE) Program

Our research centers on understanding adeno-associated virus (AAV) and utilizing our knowledge to develop gene therapy vector platforms to treat human diseases.

  • Capsid Discovery and Characterization

    • Using high-throughtput sequencing strategies, we aim to discover and characterize natural AAV capsid sequences for their potential use as gene therapy vectors.
  • Development of Quality Control Workflows for Gene Therapy Vectors 

    • One understudied aspect of gene therapy vectorology is the relative frequency of heterogeneic bi-products in the form of genomic impurities, truncations, and chimeric vector sequences.  We seek to develop NGS and bioinformatics tools to profile preclinical and research-grade rAAVs. 
  • Vector Engineering

    • Vector safety and efficacy is controlled by multiple factors, ranging from the DNA sequence in the vector design, all the way to how the therapy is administered to the host/patient.  We aim to discover ways to improve upon vector design to ensure safe and potent treatments.
  • Immunology

    • The host immune response towards foreign antigens is the most challenging hurdle for gene therapy.  Nonetheless, Immunology remains the most complex area of study for understanding why vector-based gene therapies fall short of fully treating disease.
  • Virology

    • To understand how vector-based gene therapies interacti with the host/patient, address why these tools work the way they do, and modulate them further to enhance their biological properties, it is imperitive to improve our knowledge of how wild-type viruses function and their mechanisms of their complex life-cycles.